{
  "timestamp": "2026-01-20T00:45:51.076268",
  "method": "llm",
  "judge_model": "claude-3-haiku-20240307",
  "source_file": "/Users/shloknatarajan/stanford/research/daneshjou/autogkb-benchmark/src/experiments/sentence_generation/llm_judge_ask/outputs/gpt-5_v4_20260120_004545.json",
  "overall_avg_score": 0.767,
  "num_pmcids": 1,
  "per_pmcid": [
    {
      "pmcid": "PMC12036300",
      "avg_score": 0.767,
      "num_variants": 3,
      "per_variant": [
        {
          "variant": "CYP2C19*1",
          "ground_truth": [
            "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
            "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."
          ],
          "generated": [
            "CYP2C19 *1/*1 is not associated with increased risk of major adverse cardiovascular events when treated with a doubled maintenance dose of clopidogrel (150 mg/day) as compared to carriers of CYP2C19*2."
          ],
          "score": 0.7,
          "best_similarity": 0.45714285714285713,
          "best_gt": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
          "best_gen": "CYP2C19 *1/*1 is not associated with increased risk of major adverse cardiovascular events when treated with a doubled maintenance dose of clopidogrel (150 mg/day) as compared to carriers of CYP2C19*2."
        },
        {
          "variant": "CYP2C19*2",
          "ground_truth": [
            "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
            "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."
          ],
          "generated": [
            "CYP2C19*2 carrier genotypes (single-copy carriers) are not associated with increased risk of major acute cardiovascular events (MACE) when treated with a doubled maintenance dose of clopidogrel (150 mg/day) as compared to non-carriers."
          ],
          "score": 0.8,
          "best_similarity": 0.35,
          "best_gt": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
          "best_gen": "CYP2C19*2 carrier genotypes (single-copy carriers) are not associated with increased risk of major acute cardiovascular events (MACE) when treated with a doubled maintenance dose of clopidogrel (150 mg/day) as compared to non-carriers."
        },
        {
          "variant": "CYP2C19*17",
          "ground_truth": [
            "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
            "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."
          ],
          "generated": [
            "Allele CYP2C19*17 is not associated with increased risk of bleeding when treated with a doubled maintenance dose of clopidogrel (150 mg/day) after PCI as compared to non-carriers."
          ],
          "score": 0.8,
          "best_similarity": 0.36363636363636365,
          "best_gt": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
          "best_gen": "Allele CYP2C19*17 is not associated with increased risk of bleeding when treated with a doubled maintenance dose of clopidogrel (150 mg/day) after PCI as compared to non-carriers."
        }
      ],
      "generated_extras": []
    }
  ]
}